European Specialty Pharma In Transition: Is A U.S. Presence Necessary?
European-based specialty pharma is at a crossroads. For several of the current generation of Shire PLC hopefuls – companies whose strategy, broadly defined, is focused on late-stage in-licensing and commercialization – 2011 could prove a transformational and, for some, a make-or-break year.
You may also be interested in...
Small European biotechs usually build their business in their home region first, and later look to the US for growth. Belgium's ThromboGenics is doing the opposite; it aims to launch its lead product initially in the US, and will tackle Europe after partner and market leader Alcon paves the way.
U.S approval of orphan drug Erwinase puts specialty pharma firm EUSA on new growth trajectory, showing the value of its strategy to build a transatlantic infrastructure for niche products – and transitioning it from a commercially-focused to a development-capable organization.
Many struggling European specialty pharma companies are grappling with whether to move outside the traditional business mold by venturing beyond Europe, including into emerging markets, and how to develop differentiated products with potential for transformative growth.